Prime Medicine (PRME) Competitors $4.76 +0.41 (+9.31%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. VCEL, BEAM, BLTE, IDYA, HRMY, IRON, CNTA, APGE, ADPT, and SRPTShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Vericel (VCEL), Beam Therapeutics (BEAM), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), Apogee Therapeutics (APGE), Adaptive Biotechnologies (ADPT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Vericel Beam Therapeutics Belite Bio IDEAYA Biosciences Harmony Biosciences Disc Medicine Centessa Pharmaceuticals Apogee Therapeutics Adaptive Biotechnologies Sarepta Therapeutics Vericel (NASDAQ:VCEL) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends. Which has more risk and volatility, VCEL or PRME? Vericel has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Do analysts rate VCEL or PRME? Vericel presently has a consensus target price of $61.14, suggesting a potential upside of 52.33%. Prime Medicine has a consensus target price of $10.08, suggesting a potential upside of 112.06%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is VCEL or PRME more profitable? Vericel has a net margin of 1.25% compared to Prime Medicine's net margin of 0.00%. Vericel's return on equity of 1.09% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.25% 1.09% 0.73% Prime Medicine N/A -107.87%-74.97% Which has better valuation and earnings, VCEL or PRME? Vericel has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$238.54M8.47$10.36M$0.031,337.93Prime Medicine$3.85M166.28-$198.13M-$1.61-2.95 Do institutionals and insiders have more ownership in VCEL or PRME? 70.4% of Prime Medicine shares are held by institutional investors. 5.2% of Vericel shares are held by company insiders. Comparatively, 22.9% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to VCEL or PRME? In the previous week, Prime Medicine had 1 more articles in the media than Vericel. MarketBeat recorded 4 mentions for Prime Medicine and 3 mentions for Vericel. Vericel's average media sentiment score of 1.87 beat Prime Medicine's score of 0.92 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prime Medicine 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVericel beats Prime Medicine on 10 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$632.79M$226.89M$5.53B$20.66BDividend YieldN/AN/A5.06%3.71%P/E Ratio-2.30N/A28.5827.84Price / Sales166.28296.18371.5855.57Price / CashN/A22.4424.7217.94Price / Book3.477.098.264.60Net Income-$198.13M-$100.37M$3.19B$989.58M7 Day Performance25.13%10.39%5.16%1.12%1 Month Performance225.68%11.08%9.11%5.43%1 Year Performance-16.73%12.25%30.07%10.55% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.9005 of 5 stars$4.76+9.3%$10.08+112.1%-23.8%$632.79M$3.85M-2.30234VCELVericel3.7775 of 5 stars$39.41-5.6%$61.14+55.1%-17.7%$1.98B$237.22M1,314.10300News CoveragePositive NewsBEAMBeam Therapeutics2.1087 of 5 stars$19.18-4.1%$48.75+154.2%-21.3%$1.93B$63.52M-4.16510BLTEBelite Bio2.0184 of 5 stars$58.63-1.4%$96.67+64.9%+28.6%$1.87BN/A-43.1110IDYAIDEAYA Biosciences3.602 of 5 stars$21.16-4.3%$53.42+152.4%-43.8%$1.85B$7M-5.8980HRMYHarmony Biosciences4.8555 of 5 stars$32.24+0.2%$53.63+66.3%+0.7%$1.85B$714.73M12.31200Positive NewsIRONDisc Medicine3.229 of 5 stars$53.38-2.5%$96.70+81.2%+20.6%$1.85BN/A-13.6230Insider TradeCNTACentessa Pharmaceuticals3.2435 of 5 stars$13.62-3.2%$27.89+104.8%+46.3%$1.82B$15M-7.52200APGEApogee Therapeutics3.1013 of 5 stars$39.24-17.3%$99.00+152.3%-20.6%$1.81BN/A-10.9091High Trading VolumeADPTAdaptive Biotechnologies2.871 of 5 stars$11.74-0.5%$10.57-10.0%+195.5%$1.78B$178.96M-12.23790SRPTSarepta Therapeutics4.7035 of 5 stars$17.32-5.0%$60.88+251.5%-88.1%$1.70B$1.90B-6.441,372Trending NewsAnalyst Revision Related Companies and Tools Related Companies Vericel Alternatives Beam Therapeutics Alternatives Belite Bio Alternatives IDEAYA Biosciences Alternatives Harmony Biosciences Alternatives Disc Medicine Alternatives Centessa Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Adaptive Biotechnologies Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts